Pub Date : 2020-06-15DOI: 10.2174/1874143602010010001
Gul Ambreen, A. Siddiq, K. Hussain, Sadia Baig
Healthy adult rabbits of local strain were divided into 5 groups (n= 8). The study was divided into 2 phases. Phase I: oil feeding; the first set of rabbits served as control and fed on a normal rabbit diet. Four sets of rabbits were treated for 16 weeks with 1 ml/kg/day of single time heated olive (STH-OO), canola (STH-CO), sunflower oils (STH-SO) or a mixture of these oils (STH-MVO). In phase II: TPN was given to each group, including the control group, for 2 weeks. Before and after TPN therapy, body and liver weights were measured. Plasma lipid profile [triglycerides, total cholesterol, high-density lipoproteins, low-density lipoproteins, very-low-density lipoproteins], liver function marker [total-protein, albumin, total and direct bilirubin, serum glutamic pyruvic transaminase, serum glutamic-oxaloacetic transaminase, gamma-glutamyl transferase, and alkaline phosphatase], oxidative stress and tissue damage parameters [malondialdehyde, C-reactive protein, lactate dehydrogenase, and creatine phosphokinase] of all the groups weremeasured at the end of TPN therapy.
{"title":"Single Time Heated Different Vegetable Oils Use-Impact on the Magnitude of Total Parenteral Nutrition (TPN) Associated Adverse Effects","authors":"Gul Ambreen, A. Siddiq, K. Hussain, Sadia Baig","doi":"10.2174/1874143602010010001","DOIUrl":"https://doi.org/10.2174/1874143602010010001","url":null,"abstract":"Healthy adult rabbits of local strain were divided into 5 groups (n= 8). The study was divided into 2 phases. Phase I: oil feeding; the first set of rabbits served as control and fed on a normal rabbit diet. Four sets of rabbits were treated for 16 weeks with 1 ml/kg/day of single time heated olive (STH-OO), canola (STH-CO), sunflower oils (STH-SO) or a mixture of these oils (STH-MVO). In phase II: TPN was given to each group, including the control group, for 2 weeks. Before and after TPN therapy, body and liver weights were measured. Plasma lipid profile [triglycerides, total cholesterol, high-density lipoproteins, low-density lipoproteins, very-low-density lipoproteins], liver function marker [total-protein, albumin, total and direct bilirubin, serum glutamic pyruvic transaminase, serum glutamic-oxaloacetic transaminase, gamma-glutamyl transferase, and alkaline phosphatase], oxidative stress and tissue damage parameters [malondialdehyde, C-reactive protein, lactate dehydrogenase, and creatine phosphokinase] of all the groups weremeasured at the end of TPN therapy.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"39 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79053479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-15DOI: 10.2174/1874143601909010005
Geeta Deswal, Kumar Guarve, P. Kriplani, A. Dhingra, B. Chopra, J. Sidana
The preliminary phytochemical studies confirmed the existence of saponins, carbohydrates, tannins, and flavonoids. CCl4 treated group boost the concentrations of Serum Glutamate Pyruvate Transaminase (SGPT), Serum Glutamate Oxaloacetate Transaminase (SGOT), Alkaline Phosphate (ALP) and serum bilirubin as compared to control group (rats treated with vehicle). The methanolic extract of plant (200 mg/kg & 400 mg/kg) and standard drug silymarin (100 mg/kg) produced a significant decrease in raised levels of these enzymes as compared to control.
{"title":"Hepatoprotective Activity of Tectona grandis Against CCl4-Induced Hepatic Damage in Rats","authors":"Geeta Deswal, Kumar Guarve, P. Kriplani, A. Dhingra, B. Chopra, J. Sidana","doi":"10.2174/1874143601909010005","DOIUrl":"https://doi.org/10.2174/1874143601909010005","url":null,"abstract":"The preliminary phytochemical studies confirmed the existence of saponins, carbohydrates, tannins, and flavonoids. CCl4 treated group boost the concentrations of Serum Glutamate Pyruvate Transaminase (SGPT), Serum Glutamate Oxaloacetate Transaminase (SGOT), Alkaline Phosphate (ALP) and serum bilirubin as compared to control group (rats treated with vehicle). The methanolic extract of plant (200 mg/kg & 400 mg/kg) and standard drug silymarin (100 mg/kg) produced a significant decrease in raised levels of these enzymes as compared to control.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"11 1","pages":"5-11"},"PeriodicalIF":0.0,"publicationDate":"2019-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84445936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-15DOI: 10.2174/1874143601909010001
R. Pal, A. Mishra
Dhatryadi ghrita consists of dhatri, is known to have number of curative properties since ages. It does not causes any toxic or adverse effect, but there is no scientific evidence available.The present piece of research is aimed to study the toxic effects in order to lay down the safety parameters of methanolic extract obtained from Dhatryadi Ghrita in wistar rats (180-200g) as per the standards set by The Organization for Economic Cooperation and Development or OECD.Group 1 was used as a control for comparing the behavior of rats from all groups which were administered extracts of different concentrations. The animals in Group 2 were administered a dose of 1000, Group 3, 2000, and Group 4, 3000, respectively in the units of mg/kg and Group 5 were given a dose of 4000 mg/kg accordingly.The acute toxicity studies of the experiment dealing with different doses as varying from 1000-4000 mg/kg, which did not resulted in any death of any animal till 14 days of observation in the experimentation period.Dhatryadi Ghrita is safe in rodent and mice. Hence, the extract is safer for therapeutic use in pharmaceutical formulations. Ghrita in different concentrations were found to be completely safe and non-toxic under acute toxicity studies.
{"title":"Evaluation of Acute Toxicity of the Methanolic Extract of Dhatryadi Ghrita in Wistar Rats","authors":"R. Pal, A. Mishra","doi":"10.2174/1874143601909010001","DOIUrl":"https://doi.org/10.2174/1874143601909010001","url":null,"abstract":"Dhatryadi ghrita consists of dhatri, is known to have number of curative properties since ages. It does not causes any toxic or adverse effect, but there is no scientific evidence available.The present piece of research is aimed to study the toxic effects in order to lay down the safety parameters of methanolic extract obtained from Dhatryadi Ghrita in wistar rats (180-200g) as per the standards set by The Organization for Economic Cooperation and Development or OECD.Group 1 was used as a control for comparing the behavior of rats from all groups which were administered extracts of different concentrations. The animals in Group 2 were administered a dose of 1000, Group 3, 2000, and Group 4, 3000, respectively in the units of mg/kg and Group 5 were given a dose of 4000 mg/kg accordingly.The acute toxicity studies of the experiment dealing with different doses as varying from 1000-4000 mg/kg, which did not resulted in any death of any animal till 14 days of observation in the experimentation period.Dhatryadi Ghrita is safe in rodent and mice. Hence, the extract is safer for therapeutic use in pharmaceutical formulations. Ghrita in different concentrations were found to be completely safe and non-toxic under acute toxicity studies.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75731184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-30DOI: 10.2174/1874143601808010021
P. Yadav, Goutam Rath, Gazal Sharma, Ranjit Singh, A. Goyal
Anti-angiogenic therapy can produce transient regression in tumor in case of Glioblastoma (GBM); however, no prolongation of patient survival rate had so far been achieved.To address this problem, an effort was made to design and characterize a temozolomide loaded nanosystem for targeting the tumor vasculature in the brain using polymeric nanoparticles. It included the formation of Temozolomide (TMZ) loaded Solid-Lipid Nanoparticles (SLNs) and their conjugation with polysorbate-80 (P-80) which enhanced the penetration of drug to blood-brain barrier resulting in the enhancement of pro-apoptotic activity.Conjugating nanoparticles with a tumor-penetrating polymer (P-80) further enhanced the therapeutic efficacy of the drug.The animal studies indicated the enhanced potential of the developed system in the effective treatment of glioblastoma.
{"title":"Polysorbate 80 Coated Solid Lipid Nanoparticles for the Delivery of Temozolomide Into the Brain","authors":"P. Yadav, Goutam Rath, Gazal Sharma, Ranjit Singh, A. Goyal","doi":"10.2174/1874143601808010021","DOIUrl":"https://doi.org/10.2174/1874143601808010021","url":null,"abstract":"Anti-angiogenic therapy can produce transient regression in tumor in case of Glioblastoma (GBM); however, no prolongation of patient survival rate had so far been achieved.To address this problem, an effort was made to design and characterize a temozolomide loaded nanosystem for targeting the tumor vasculature in the brain using polymeric nanoparticles. It included the formation of Temozolomide (TMZ) loaded Solid-Lipid Nanoparticles (SLNs) and their conjugation with polysorbate-80 (P-80) which enhanced the penetration of drug to blood-brain barrier resulting in the enhancement of pro-apoptotic activity.Conjugating nanoparticles with a tumor-penetrating polymer (P-80) further enhanced the therapeutic efficacy of the drug.The animal studies indicated the enhanced potential of the developed system in the effective treatment of glioblastoma.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75962672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The main objective of this study was to evaluate the biological activity of an ASA (Amino-Steroid-Anthracenone derivative) against heart failure caused by the ischemia- reperfusion injury (translated as infarct area). Biological activity exerted by ASA (0.001-100 nM) on infarct area was determined using an ischemia-reperfusion injury model. In addition, to characterize the molecular mechanism involved in the effect exerted by ASA on left ventricular pressure, some drugs such as estrone (0.001-100 nM), tamoxifen (1 nM), butoxamine (1 nM) and ZM-241385 (1 nM) were used. The experimental data showed that ASA decreased the infarction area significantly (p = 0.05) compared to estrone. Other results indicated that ASA decreased left ventricular pressure and this effect was inhibited by ZM-241385. In addition, ASA increased cAMP levels in a time-dependent manner compared to control conditions. The results showed that ASA decreases ischemia-reperfusion injury (translated as infarct area) via A2 adenosine receptor activation and these phenomena involve changes in cAMP levels.
{"title":"New Amino-steroid-anthracenone with Biological Activity Against Ischemia-reperfusion Injury in a Wistar Rat Model","authors":"Figueroa‐Valverde Lauro, Rosas-Nexticapa Marcela, Mateu-Armand Virginia, Herrera-Meza Socorro, D. Francisco, Montano-Tapia Elizabeth, García-Cervera Elodia, Pool-Gómez Eduardo, Hau-Heredia Lenin, García-Martínez Rolando, López-Ramos Maria, Cauich-Carrillo Regina, P. Perla","doi":"10.2174/1874143601808010010","DOIUrl":"https://doi.org/10.2174/1874143601808010010","url":null,"abstract":"\u0000 \u0000 The main objective of this study was to evaluate the biological activity of an ASA (Amino-Steroid-Anthracenone derivative) against heart failure caused by the ischemia- reperfusion injury (translated as infarct area).\u0000 \u0000 \u0000 \u0000 Biological activity exerted by ASA (0.001-100 nM) on infarct area was determined using an ischemia-reperfusion injury model. In addition, to characterize the molecular mechanism involved in the effect exerted by ASA on left ventricular pressure, some drugs such as estrone (0.001-100 nM), tamoxifen (1 nM), butoxamine (1 nM) and ZM-241385 (1 nM) were used.\u0000 \u0000 \u0000 \u0000 The experimental data showed that ASA decreased the infarction area significantly (p = 0.05) compared to estrone. Other results indicated that ASA decreased left ventricular pressure and this effect was inhibited by ZM-241385. In addition, ASA increased cAMP levels in a time-dependent manner compared to control conditions.\u0000 \u0000 \u0000 \u0000 The results showed that ASA decreases ischemia-reperfusion injury (translated as infarct area) via A2 adenosine receptor activation and these phenomena involve changes in cAMP levels.\u0000","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75376714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-31DOI: 10.2174/1874143601808010001
H. Famitafreshi, M. Karimian
Social isolation is associated with adverse effects on brain functions. According to previous studies, the reduction of oxidative stress improves cognitive functions. Memory performance is dependent on hippocampus and prefrontal function. The aim of this study is to show that impairment of memory in object recognition test in isolation state is accompanied by deregulation of oxidative stress balance in related areas.In this study, 14 male Sprague-Dawley rats were randomly divided into two groups as follows: social and isolation. Socialization and isolation plus one week of acclimatization occurred for fourteen days. At the end of the study, after performing behavioral test, (novel object recognition test) rats were anesthetized and sacrificed. After preparation of tissues in controlled condition, oxidative stress status in hippocampus and prefrontal cortex for Malondialdehyde (MDA), glutathione and nitrite/nitrate was assessed.MDA in the hippocampus and prefrontal cortex was higher in isolated rats compared to social rats. Glutathione and nitrite/nitrate in the hippocampus and prefrontal cortex were lower in isolated rats compared to social rats. Memory performance in novel object recognition test both in short term and long term was better in social rats.Memory performance in novel object recognition test is influenced by social and oxidative stress status. So improving memory is possible through socialization and improvement of antioxidant status.
{"title":"Social State Influences Memory in Novel Object Recognition Test Through Oxidative Stress Balance in Male Rats","authors":"H. Famitafreshi, M. Karimian","doi":"10.2174/1874143601808010001","DOIUrl":"https://doi.org/10.2174/1874143601808010001","url":null,"abstract":"Social isolation is associated with adverse effects on brain functions. According to previous studies, the reduction of oxidative stress improves cognitive functions. Memory performance is dependent on hippocampus and prefrontal function. The aim of this study is to show that impairment of memory in object recognition test in isolation state is accompanied by deregulation of oxidative stress balance in related areas.In this study, 14 male Sprague-Dawley rats were randomly divided into two groups as follows: social and isolation. Socialization and isolation plus one week of acclimatization occurred for fourteen days. At the end of the study, after performing behavioral test, (novel object recognition test) rats were anesthetized and sacrificed. After preparation of tissues in controlled condition, oxidative stress status in hippocampus and prefrontal cortex for Malondialdehyde (MDA), glutathione and nitrite/nitrate was assessed.MDA in the hippocampus and prefrontal cortex was higher in isolated rats compared to social rats. Glutathione and nitrite/nitrate in the hippocampus and prefrontal cortex were lower in isolated rats compared to social rats. Memory performance in novel object recognition test both in short term and long term was better in social rats.Memory performance in novel object recognition test is influenced by social and oxidative stress status. So improving memory is possible through socialization and improvement of antioxidant status.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"86 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82941341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-30DOI: 10.2174/1874143620130805001
Andrea Hobson, Julia I. Baines, M. Weiss
Neonatal encephalopathy remains a significant cause of death and disability worldwide. Therapeutic hypothermia has become a mainstay of therapy and has demonstrated the potential for neuroprotection and repair after neonatal hypoxic-ischemic brain injury. However, it has become apparent from published trials that hypothermia alone will not serve as complete protection nor benefit all neonates. The complicated cascade of events in a hypoxic-ischemic insult lends itself to multiple types of therapy, making a multi-faceted approach to treatment attractive. This review critically discusses the broad range of medical therapies currently being studied and summarizes the animal and human studies that have been done to date. Therapies that may act synergistically with cooling therapy are also discussed.
{"title":"Beyond Hypothermia: Alternative Therapies for Hypoxic Ischemic Encephalopathy","authors":"Andrea Hobson, Julia I. Baines, M. Weiss","doi":"10.2174/1874143620130805001","DOIUrl":"https://doi.org/10.2174/1874143620130805001","url":null,"abstract":"Neonatal encephalopathy remains a significant cause of death and disability worldwide. Therapeutic hypothermia has become a mainstay of therapy and has demonstrated the potential for neuroprotection and repair after neonatal hypoxic-ischemic brain injury. However, it has become apparent from published trials that hypothermia alone will not serve as complete protection nor benefit all neonates. The complicated cascade of events in a hypoxic-ischemic insult lends itself to multiple types of therapy, making a multi-faceted approach to treatment attractive. This review critically discusses the broad range of medical therapies currently being studied and summarizes the animal and human studies that have been done to date. Therapies that may act synergistically with cooling therapy are also discussed.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"1 1","pages":"26-40"},"PeriodicalIF":0.0,"publicationDate":"2013-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88226796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-19DOI: 10.2174/1874143601307010002
S. Ballali, D. Chiffi, M. Trojniak, D. Gregori
Objective: To evaluate the impact of multitargeted tyrosine kinase inhibitors (TKI) considering 1 st and 2 nd line treatment for a full period of 3 years in the eligible patients of Veneto Region. Methods: A Markov state decision model was selected to evaluate the cost impact of sunitinib and sorafenib use for a lapse of time of three years in Veneto public hospitals, considering transition probabilities from three different states and by comparing the expected deaths and the monthly survival rates in treatment and no-treatment groups. Results: From the initial cohort of 357 patients eligible for sunitinib treatment, stable ones (139) were considered in order to evaluate the impact of the multitargeted agent on overall progression of the disease. Results showed that a smaller portion of patients receiving sunitinib transited from a stable to a progressive state, with respect to the patients who were not receiving sunitinib. The cost of 6 months treatment with sunitinib reached a median value of 2532666� , increasing till 3607807� as cumulative amount at 12 months. Costs after the 1 st year flattened around the same figure (3800000� ) due to the transition towards death or 2 nd line treatments. Discussion: the costs of the first 6 months therapy with sunitinib have a very high impact on public health expenses in the Regione Veneto. 2 nd line treatment with sorafenib instead increased overall expenses of a reduced proportion, due to the small proportion of patients undergoing this treatment and the relative inferior cost of the drug. Conclusion: From what came out from our simulated model on costs borne by the SSN for the treatment of patients with mRCC, we can conclude that they are effective on the progression of the disease the greatest impact being the cost for the 1 st line pharmacological treatment.
{"title":"Economic Impact of Sunitinib and Sorafenib Use in Metastatic Renal Cell Carcinoma Treatment in Veneto Region, Italy","authors":"S. Ballali, D. Chiffi, M. Trojniak, D. Gregori","doi":"10.2174/1874143601307010002","DOIUrl":"https://doi.org/10.2174/1874143601307010002","url":null,"abstract":"Objective: To evaluate the impact of multitargeted tyrosine kinase inhibitors (TKI) considering 1 st and 2 nd line treatment for a full period of 3 years in the eligible patients of Veneto Region. Methods: A Markov state decision model was selected to evaluate the cost impact of sunitinib and sorafenib use for a lapse of time of three years in Veneto public hospitals, considering transition probabilities from three different states and by comparing the expected deaths and the monthly survival rates in treatment and no-treatment groups. Results: From the initial cohort of 357 patients eligible for sunitinib treatment, stable ones (139) were considered in order to evaluate the impact of the multitargeted agent on overall progression of the disease. Results showed that a smaller portion of patients receiving sunitinib transited from a stable to a progressive state, with respect to the patients who were not receiving sunitinib. The cost of 6 months treatment with sunitinib reached a median value of 2532666� , increasing till 3607807� as cumulative amount at 12 months. Costs after the 1 st year flattened around the same figure (3800000� ) due to the transition towards death or 2 nd line treatments. Discussion: the costs of the first 6 months therapy with sunitinib have a very high impact on public health expenses in the Regione Veneto. 2 nd line treatment with sorafenib instead increased overall expenses of a reduced proportion, due to the small proportion of patients undergoing this treatment and the relative inferior cost of the drug. Conclusion: From what came out from our simulated model on costs borne by the SSN for the treatment of patients with mRCC, we can conclude that they are effective on the progression of the disease the greatest impact being the cost for the 1 st line pharmacological treatment.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"75 1","pages":"2-8"},"PeriodicalIF":0.0,"publicationDate":"2013-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86401647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-19DOI: 10.2174/1874143601307010017
S. Ballali, D. Chiffi, M. Trojniak, D. Gregori
Objective: To assess the economic impact of the introduction of trastuzumab and lapatinib, as 1st and 2nd line treatment of HER-2 (Human Epidermal Growth Factor Receptor 2)-positive mBC (metastatic breast cancer) patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of trastuzumab and lapatinib use for a lapse of time of three years in Veneto public hospitals. The Markov model expressed transition probabilities from three different states, comparing in addition the expected deaths and the monthly survival rates in treatment and no- treatment groups, along the lines of previously published studies. Results: From the initial cohort of 267 patients eligible for treatment, stable ones (195) were considered in order to evaluate the impact of the targeted therapy on overall progression of the disease. Trastuzumab administration accounted for a regional expense of 2765662 � within the 6 months, almost duplicating in 1 year. 2 nd line therapy accounted on the 6 months budget for almost 100000 � , costs overseen for the eligible patients at the beginning. All costs were considered together with the associated drug. Costs of second line treatment increased within the last year, taken the higher number of patients transiting from a stable condition to a progressive one. Conclusion: Our result pointed out that mBC represents a considerably high cost also from a regional perspective. Economic evaluations are usually performed in different countries at national level, while in local health care decision making there is lack of health economic data and evaluations.
{"title":"Evaluating Trastuzumab and Lapatinib's Economic Impact in the Treatment of Metastatic Breast Cancer in Veneto Region Cohort","authors":"S. Ballali, D. Chiffi, M. Trojniak, D. Gregori","doi":"10.2174/1874143601307010017","DOIUrl":"https://doi.org/10.2174/1874143601307010017","url":null,"abstract":"Objective: To assess the economic impact of the introduction of trastuzumab and lapatinib, as 1st and 2nd line treatment of HER-2 (Human Epidermal Growth Factor Receptor 2)-positive mBC (metastatic breast cancer) patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of trastuzumab and lapatinib use for a lapse of time of three years in Veneto public hospitals. The Markov model expressed transition probabilities from three different states, comparing in addition the expected deaths and the monthly survival rates in treatment and no- treatment groups, along the lines of previously published studies. Results: From the initial cohort of 267 patients eligible for treatment, stable ones (195) were considered in order to evaluate the impact of the targeted therapy on overall progression of the disease. Trastuzumab administration accounted for a regional expense of 2765662 � within the 6 months, almost duplicating in 1 year. 2 nd line therapy accounted on the 6 months budget for almost 100000 � , costs overseen for the eligible patients at the beginning. All costs were considered together with the associated drug. Costs of second line treatment increased within the last year, taken the higher number of patients transiting from a stable condition to a progressive one. Conclusion: Our result pointed out that mBC represents a considerably high cost also from a regional perspective. Economic evaluations are usually performed in different countries at national level, while in local health care decision making there is lack of health economic data and evaluations.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"33 1","pages":"17-25"},"PeriodicalIF":0.0,"publicationDate":"2013-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76923877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-19DOI: 10.2174/1874143601307010009
S. Ballali, D. Chiffi, M. Trojniak, D. Gregori
Objective: To assess the economic impact of the introduction of bevacizumab and cetuximab, in 1st and 2nd line treatment of mCRC patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of bevacizumab and cetuximab use in patients with mCRC for a lapse of time of three years in Veneto public hospitals. The Markov model expressed transition probabilities from three different states, comparing in addition the expected deaths and the monthly survival rates in treatment and no-treatment groups, along the lines of previously published studies. Results: The cost impact of bevacizumab administration in patients with mCRC accounted a mean value of 18268788 � within the first 6 months. Cetuximab therapy for those refractory to 1 st line treatment, increased costs of almost 833340 � in the first 6 months, increasing in the following period due to a higher portion of patients switching from a stable status to a progressive one. Discussion: The cost impact of monoclonal antibodies on health expenses is very high. For a regional cohort like the Veneto's one, figure sets around 19000000 � in 6 months, when considering 1 st and 2 nd line treatment, reaching the level
{"title":"Cost Impact of Bevacizumab and Cetuximab Associated Therapies in Colorectal Cancer in Veneto Region","authors":"S. Ballali, D. Chiffi, M. Trojniak, D. Gregori","doi":"10.2174/1874143601307010009","DOIUrl":"https://doi.org/10.2174/1874143601307010009","url":null,"abstract":"Objective: To assess the economic impact of the introduction of bevacizumab and cetuximab, in 1st and 2nd line treatment of mCRC patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of bevacizumab and cetuximab use in patients with mCRC for a lapse of time of three years in Veneto public hospitals. The Markov model expressed transition probabilities from three different states, comparing in addition the expected deaths and the monthly survival rates in treatment and no-treatment groups, along the lines of previously published studies. Results: The cost impact of bevacizumab administration in patients with mCRC accounted a mean value of 18268788 � within the first 6 months. Cetuximab therapy for those refractory to 1 st line treatment, increased costs of almost 833340 � in the first 6 months, increasing in the following period due to a higher portion of patients switching from a stable status to a progressive one. Discussion: The cost impact of monoclonal antibodies on health expenses is very high. For a regional cohort like the Veneto's one, figure sets around 19000000 � in 6 months, when considering 1 st and 2 nd line treatment, reaching the level","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"41 1","pages":"9-16"},"PeriodicalIF":0.0,"publicationDate":"2013-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88684585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：